Cell Therapy News

Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.

Despite an overall positive safety outlook, the scope of potential toxicities related to chimeric antigen receptor T-cell therapy remains unclear due to lack of long-term follow-up.

Crystal L. Mackall, MD, will receive this year’s Edward Netter Leadership Award from Alliance for Cancer Gene Therapy.

In this episode, host Shikha Jain, MD, speaks with Isabelle Choi, MD, about the use of proton therapy in radiation oncology, improving accessibility to radiation technology and more.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.

Carl H. June, MD, will receive this year’s AACR Award for Lifetime Achievement in Cancer Research.

Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today.

Local administration of chimeric antigen receptor T cells via a fibrin-based gel effectively eliminated leftover cancer cells after incomplete surgical resection, study results published in Science Advances showed.

Adults with advanced multiple myeloma and renal insufficiency treated with idecabtagene vicleucel achieved similar outcomes as those with normal renal function, according to retrospective study results.

A small percentage of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a second infusion of tisagenlecleucel had clinically meaningful responses, data from a retrospective study showed.